Utah Doctor's Fentanyl Lies Lead to Permanent DEA Registration Revocation
Published Date: 1/15/2026
Notice
Summary
Dr. Mark Huff from Utah lost his DEA license because he wasn’t honest about his fentanyl abuse and treatment during a government investigation. The DEA decided his actions could harm public safety, so they ended his registration. This means Dr. Huff can no longer legally handle controlled substances, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked for Dr. Mark Huff
Dr. Mark Huff’s DEA Certificate of Registration No. FH6657716 is revoked, effective February 17, 2026. This means Dr. Huff can no longer legally handle controlled substances and the revocation applies immediately on that date.
Pending DEA Applications Denied
The Order also denies any pending applications of Mark Huff to renew or modify DEA registration and denies any other pending application for additional registration in Utah, effective February 17, 2026. Those pending requests will not be granted after that date.
Patients May Lose Access To Controlled Drugs
Patients of Dr. Mark Huff may no longer receive prescriptions or other legally authorized access to controlled substances from him after February 17, 2026. The Order explicitly notes the revocation impacts his medical practice and patients.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-00613 — Notice of Request for Revision to and Extension of Approval of an Information Collection; Communicable Diseases in Horses
The USDA wants to update and keep collecting info about horses that test positive for a contagious disease called equine infectious anemia. This affects horse owners, vets, and labs that test horses moving between states. They’re asking for public comments by March 16, 2026, and the changes won’t cost anyone extra but will help keep horses healthy and safe.
Next: 2026-00622 — Proviso Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Proviso Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Berkeley, Illinois, used for moving goods like paper and lumber. This change kicks in on January 29, 2026, with no big money shifts expected since Proviso’s revenue stays small. The move keeps future rail connections open and promises smooth cargo swaps with Union Pacific Railroad.